thymic-factor--circulating and Burns

The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation, normalization of fibrinolysis, influenced the content of pro-inflammatory and anti-inflammatory cytokins. It allowed to shorten the terms of the first autodermoplasty at an average by 5 days and to make staying of burned patients at the hospital 11 days shorter.

Topics: Adjuvants, Immunologic; Adolescent; Adult; Blood Coagulation; Blood Coagulation Tests; Burns; Cytokines; Female; Humans; Immunoenzyme Techniques; Interleukins; Length of Stay; Male; Skin Transplantation; Thymus Hormones; Tumor Necrosis Factor-alpha

Addition of immunomodulating therapy with Thymalin, a thymus agent, to the multimodality therapy of burnt patients contributes to a rapid normalization of immunological parameters. The most marked immune response was observed 7-10 days after a therapy course initiated in the early periods of burn disease in patients with severely depressed T-system immunity and a high sensitivity to the drug. Inclusion of a donor blood leukomass transfusion course activates the cellular link of the immune system just after the treatment course, but fails to favour a stable normalization of thymus-dependent lymphocyte ratios.

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Blood Transfusion; Burns; Combined Modality Therapy; Humans; Leukocyte Count; Lymphopenia; Middle Aged; T-Lymphocytes; Thymus Hormones

Topics: Adjuvants, Immunologic; Burns; Humans; Thymus Hormones; Wound Healing